Suchen
BioMarin Pharmaceutical Inc
BMRNZur Watchlist hinzufügen
57.410USD
-0.260-0.45%
Handelsschluss 06/29, 16:00（ET）Kurse um 15 Minuten verzögert
11.10BMarktkapitalisierung
41.15KGV TTM
mehr Informationen über BioMarin Pharmaceutical Inc Unternehmen
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Inc Informationen
BörsenkürzelBMRN
Name des UnternehmensBioMarin Pharmaceutical Inc
IPO-datumJul 23, 1999
CEOHardy (Alexander)
Anzahl der mitarbeiter3040
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
Addresse770 Lindaro Street
StadtSAN RAFAEL
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94901
Telefon14155066700
Websitehttps://www.biomarin.com/
BörsenkürzelBMRN
IPO-datumJul 23, 1999
CEOHardy (Alexander)
Führungskräfte von BioMarin Pharmaceutical Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
3.71K
-62.46%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
42.71K
+17.54%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
28.85K
+25.96%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
14.39K
+52.03%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
14.39K
+52.05%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von BioMarin Pharmaceutical Inc?
Die fünf größten Anteilseigner von BioMarin Pharmaceutical Inc sind: Mr. Richard A. (Randy) Meier
Wie viele Institutionen halten Anteile an BioMarin Pharmaceutical Inc (BMRN)?
Mit Stand vom 2026Q1 halten 1355 Institutionen Anteile an BioMarin Pharmaceutical Inc, mit einem Gesamtmarktwert von etwa 192.89M, was 99.80% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -14513748.00 gestiegen.
Was ist die größte Einnahmequelle von BioMarin Pharmaceutical Inc?
Am 2026Q1 erzielte das Geschäft mit Voxzogo für BioMarin Pharmaceutical Inc den höchsten Umsatz in Höhe von 926.92M, was 29.26% des Gesamtumsatzes entspricht.
